US8129187B2 Active / In Force US ⏱️ 3.3 years remaining

Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2

Assignee: Kyoto University

•

Filing: 2010-02-18

•

Granted: 2012-03-06

•

Expires: 2030-02-18

📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.

Inventors

👤 Shinya Yamanaka
👤 Kazutoshi Takahashi
👤 Keisuke Okita

Bibliographic Details

Application Number —

Jurisdiction US

Data Source google_patents

Last Synchronized 2026-11-02 14:31

CPC Classifications

C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4702; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0696; C12N2501/00; C12N2501/60; C12N2501/602; C12N2501/603; C12N2501/604; C12N2501/606; C12N2510/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/15011; C12N2740/15041; C12N2740/15043

Claims Analysis

Total Claims: 6

Claim 1

Independent Claim 99 words

A method for preparing one or more mammalian somatic cells, which comprises: (1) introducing one or more retroviral vectors comprising the following four isolated genes: Oct3/4, Klf4, c-Myc and Sox2 into a somatic cell obtained from a species of mammal and culturing the cell on a fibroblast feeder layer or extracellular matrix in a cell media that supports growth of ES cells of the mammalian species, wherein one or more induced pluripotent stem cells are obtained, and (2) inducing differentiation of the induced pluripotent stem cell obtained in (1), wherein the one or more mammalian somatic cells are obtained.

Claim 2

Independent Claim 99 words

Claim 3

Independent Claim 106 words

A method for preparing one or more mammalian somatic cells, which comprises: (1) introducing one or more retroviral vectors comprising the following three isolated genes: Oct3/4, Klf4 and Sox2 into a somatic cell obtained from a species of mammal and incubating the cell in the presence of basic fibroblast growth factor on a fibroblast feeder layer or extracellular matrix in a cell media that supports growth of ES cells of the mammalian species, wherein one or more induced pluripotent stem cells are obtained, and (2) inducing differentiation of the induced pluripotent stem cell obtained in (1), wherein the one or more mammalian somatic cells are obtained.

Claim 4

Independent Claim 106 words

Claim 5

Dependent Claim 14 words

The method of claim 1 , wherein the somatic cell is a human cell.

Claim 6

Dependent Claim 14 words

The method of claim 2 , wherein the somatic cell is a human cell.

References Cited (Backward Citations)

US4650764A Cited

US4861719A Cited

US4937190A Cited

US6605275B1 Cited

US6140111A Cited

US7070994B2 Cited

US5591624A Cited

US5716832A Cited

US5268290A Cited

US5449614A Cited

US5955331A Cited

US5266491A Cited

US5225348A Cited

US5324645A Cited

US5674980A Cited

US5652122A Cited

US5817491A Cited

US5288514A Cited

US5858740A Cited

US5834256A Cited

US6312948B1 Cited

WO1995010619A3 Cited

WO1995010619A2 Cited

US5519134A Cited

US6333195B1 Cited

US6013517A Cited

US5525735A Cited

US5549974A Cited

US6203975B1 Cited

US7029913B2 Cited

US5637456A Cited

US5707618A Cited

US5830725A Cited

US5744320A Cited

WO1997005265A1 Cited

US6521455B2 Cited

US6153745A Cited

US5910434A Cited

US6017761A Cited

US6872528B2 Cited

US20020123146A1 Cited

US6025192A Cited

US6255071B1 Cited

US6251398B1 Cited

US6017735A Cited

US6875578B2 Cited

US6365352B1 Cited

US20020174013A1 Cited

US6146874A Cited

US6660514B1 Cited

US6451595B1 Cited

US6485959B1 Cited

WO2000023567A3 Cited

WO2000023567A2 Cited

WO2000027995A1 Cited

US6521453B1 Cited

US6153432A Cited

US6312949B1 Cited

US6773920B1 Cited

US6995009B1 Cited

WO2000073423A1 Cited

US20060030041A1 Cited

US6881825B1 Cited

WO2001021767A3 Cited

WO2001021767A2 Cited

WO2001034776A1 Cited

WO2001051616A2 Cited

US20030003574A1 Cited

US6395546B1 Cited

US7439064B2 Cited

WO2001081549A2 Cited

US6833269B2 Cited

US20020090722A1 Cited

WO2002000871A2 Cited

WO2002000871A3 Cited

US6841535B2 Cited

JP2002065261A Cited

US6910434B2 Cited

WO2002061033A2 Cited

US7030292B2 Cited

US20030161817A1 Cited

JP2003009854A Cited

WO2002086134A2 Cited

WO2002086129A1 Cited

WO2002086134A3 Cited

AU2008201280A1 Cited

EP1403366A1 Cited

US7250255B2 Cited

US20040137460A1 Cited

US20060292620A1 Cited

WO2002097090A1 Cited

US20060110830A1 Cited

WO2003018780A1 Cited

US20030044976A1 Cited

US20080076176A1 Cited

US20050079606A1 Cited

US20050130144A1 Cited

US20080003560A1 Cited

US20080206865A1 Cited

US20060084172A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	2015-03-06	2015-09-05	2016-03-06	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	2019-03-06	2019-09-05	2020-03-06	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	2023-03-06	2023-09-05	2024-03-06	$7700.00	Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag

Select Category

Notes (Optional)